News

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that

For Immediate Release

Chicago, IL – August 4, 2025 – Zacks Equity Research shares Meta Platforms META as the Bull of the Day and Elevance Health ELV as the Bear of the Day. In addition, Zacks Equity

Power supplier The Southern Company SO reported second-quarter 2025 earnings per share (excluding certain one-time items) of 91 cents, outperforming the Zacks Consensus Estimate of 87 cents. The

Lindblad Expeditions (LIND) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.48 per share a year ago. These

Tyson Foods (TSN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.87 per share a year ago. These figures

Petróleo Brasileiro S.A. - Petrobras PBR is set to release second-quarter results on Aug. 7. The Zacks Consensus Estimate for earnings is 71 cents per share on revenues of $20.8 billion.

Let us

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

Concrete Pumping Holdings BBCP provides concrete pumping services and concrete waste management services primarily in U.S

Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $14.75 billion and $5.61 per share

DENTSPLY SIRONA Inc. XRAY is scheduled to release second-quarter 2025 results on Aug. 7, before the opening bell.

In the last reported quarter, the company’s earnings beat the Zacks Consensus

Agnico Eagle Mines Limited AEM reported adjusted earnings of $1.94 per share for the second quarter of 2025, up from $1.07 in the year-ago quarter. The bottom line topped the Zacks Consensus

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and

Zimmer Biomet Holdings, Inc. ZBH is scheduled to report second-quarter 2025 results on Aug. 7, before market open.

In the last reported quarter, the company’s earnings of $1.81 surpassed the Zacks

Aurora Cannabis ACB is slated to release first-quarter fiscal 2026 results on Aug. 6, before market open. The Zacks Consensus Estimate for earnings and revenues is pegged at 18 cents per share and

Cenovus Energy Inc. CVE reported second-quarter 2025 adjusted earnings per share of 33 cents, which beat the Zacks Consensus Estimate of 14 cents. The bottom line, however, declined from the

Contact center software solutions provider Five9 Inc. FIVN reported second-quarter 2025 adjusted earnings of $0.76 per share, which beat the Zacks Consensus Estimate by 16.9% and jumped 46.2% year

Twist Bioscience (TWST) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.86 per share a year ago. These figures

Huntsman Corporation’s HUN second-quarter 2025 loss (as reported) was 92 cents per share. This compares to earnings of 13 cents per share in the year-ago quarter.  Barring one-time items, adjusted

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $0.86 per share a year ago

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer

Wayfair (W) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.47 per share a year ago. These figures are

TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.04 per share a year ago. These